Cost-effectiveness analysis of adding ramucirumab to the...

Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China

Liu, Qiao, Luo, Xia, Peng, Liubao, Yi, Lidan, Wan, Xiaomin, Zeng, Xiaohui, Tan, Chongqing
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
10
Journal:
BMJ Open
DOI:
10.1136/bmjopen-2020-040691
Date:
November, 2020
File:
PDF, 1.21 MB
2020
Conversion to is in progress
Conversion to is failed